Skip Navigation


International Immunology Advance Access originally published online on July 6, 2005
International Immunology 2005 17(8):1023-1034; doi:10.1093/intimm/dxh284
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
17/8/1023    most recent
dxh284v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (11)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Tokuyama, H.
Right arrow Articles by Kakimi, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tokuyama, H.
Right arrow Articles by Kakimi, K.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


© The Japanese Society for Immunology. 2005. All rights reserved. For permissions, please e-mail: journals.permissions@oupjournals.org

The simultaneous blockade of chemokine receptors CCR2, CCR5 and CXCR3 by a non-peptide chemokine receptor antagonist protects mice from dextran sodium sulfate-mediated colitis

Hirotake Tokuyama1, Satoshi Ueha2, Makoto Kurachi3, Kouji Matsushima2, Fuminori Moriyasu1, Richard S. Blumberg4 and Kazuhiro Kakimi1,3

1 Fourth Department of Internal Medicine (Gastroenterology and Hepatology), Tokyo Medical University, Tokyo 160-0023, Japan
2 Department of Molecular Preventive Medicine and 3 Department of Immunotherapeutics (Medinet), Graduate School of Medicine, University of Tokyo, Tokyo 113-0033, Japan
4 Gastroenterology Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA

Correspondence to: K. Kakimi; E-mail: kakimi{at}m.u-tokyo.ac.jp

Chemokine receptors CCR2, CCR5 and CXCR3 are involved in the regulation of macrophage- and T cell-mediated immune responses and in the migration and activation of these cells. In order to determine whether blockade of these chemokine receptors modulates intestinal inflammation, we investigated here the effect of a non-peptide chemokine receptor antagonist, TAK-779 (N,N-dimethyl-N-[4-[[[2-(4-methylphenyl)-6,7-dihydro-5H-benzocyclohepten-8-yl]carbonyl]amino]benzyl]-tetrahydro-2H-pyran-4-aminium chloride), in mice with dextran sodium sulfate (DSS)-induced experimental colitis. C57BL/6 mice were fed 5% DSS in their drinking water for up to 7 days with or without the administration of TAK-779. The severity of inflammation in the colon was assessed by clinical signs and histological examination. Infiltration of inflammatory cells into the mucosa was analyzed by immunohistochemistry, and the expression of cytokine and chemokine mRNAs in tissues was quantitated by reverse transcription–PCR. During DSS-induced colitis, the recruitment of monocytes/macrophages into the colonic mucosa and the induction of proinflammatory cytokines correlated with the severity of intestinal inflammation. The onset of clinical signs and histopathologic features were delayed in animals treated with TAK-779. The expression of CCR2, CCR5 and CXCR3 mRNAs was inhibited in the TAK-779-treated mice. Consistent with these results, infiltration of monocytes/macrophages into the lamina propria was almost completely inhibited and the expression of colonic IL-1ß and IL-6 was significantly decreased in the TAK-779-treated mice. The blockade of CCR2, CCR5 and CXCR3 prevents murine experimental colitis by inhibiting the recruitment of inflammatory cells into the mucosa. Therefore, chemokines and their receptors may be therapeutic targets for the treatment of inflammatory bowel disease.

Keywords: chemokine, chemokine receptor, inflammatory bowel disease

Transmitting editor: M. Miyasaka


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
J. Immunol.Home page
G. T. Schnickel, S. Bastani, G. R. Hsieh, A. Shefizadeh, R. Bhatia, M. C. Fishbein, J. Belperio, and A. Ardehali
Combined CXCR3/CCR5 Blockade Attenuates Acute and Chronic Rejection
J. Immunol., April 1, 2008; 180(7): 4714 - 4721.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
B. E. Berndt, M. Zhang, G.-H. Chen, G. B. Huffnagle, and J. Y. Kao
The Role of Dendritic Cells in the Development of Acute Dextran Sulfate Sodium Colitis
J. Immunol., November 1, 2007; 179(9): 6255 - 6262.
[Abstract] [Full Text] [PDF]


Home page
GutHome page
N. Eijkelkamp, C. J Heijnen, A. Lucas, R. T Premont, S. Elsenbruch, M. Schedlowski, and A. Kavelaars
G protein-coupled receptor kinase 6 controls chronicity and severity of dextran sodium sulphate-induced colitis in mice
Gut, June 1, 2007; 56(6): 847 - 854.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Gastrointest. Liver Physiol.Home page
Y. M. Shah, K. Morimura, and F. J. Gonzalez
Expression of peroxisome proliferator-activated receptor-{gamma} in macrophage suppresses experimentally induced colitis
Am J Physiol Gastrointest Liver Physiol, February 1, 2007; 292(2): G657 - G666.
[Abstract] [Full Text] [PDF]



Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.